The company also will send letters to thousands of U.S. physicians notifying them of the risk similar to a letter it sent to Canadian physicians and pharmacists last October. The drug is approved only for schizophrenia, but is often used with elderly patients suffering from dementia and Alzheimer’s.
New drug warning
Johnson & Johnson said it plans to change the package insert of its second-best selling medicine, the antipsychotic drug Risperdal, to warn of a possible increased risk of stroke for elderly patients.
May 31st, 2003